Macrodosing and Addiction: What the Research Is Testing

Of all the areas psilocybin is being studied in, addiction has some of the more striking early results — specifically for smoking cessation and alcohol use disorder.

What has been run

A small Johns Hopkins pilot in smoking cessation reported abstinence rates at follow-up that were far above typical for the field. A later randomised trial in alcohol use disorder, published in JAMA Psychiatry, found a significant reduction in heavy drinking days versus placebo.

Two caveats that matter enormously:

• Both were conducted with substantial psychological support — preparation sessions, trained monitors present throughout, and integration afterwards. The drug was one component of a structured intervention, not the intervention itself.
• The smoking study was small and open-label. It is a signal, not a conclusion.

The mechanism people propose

Addiction involves deeply entrenched behavioural patterns. The hypothesis is that a high-dose experience produces a period of increased psychological flexibility, during which change is more possible than usual — and that therapy delivered in that window lands differently.

Note what that implies: the therapy is not optional. The trials that produced these results were not “take a dose and improve.”

Why this is not a DIY protocol

High-dose experiences can be genuinely difficult. In clinical settings they are run with screening, preparation, a controlled environment, trained people present, and structured follow-up. Those are not formalities — they are the reason the trials were safe.

If you are dealing with substance dependence, the evidence-based route is proper treatment. Watch this research, but do not try to reproduce it alone.

Read next: set and setting. Browse macrodose mushrooms.